caa a22 4500 606240659 CHVBK 20210128101309.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s00508-015-0789-4 doi (NATIONALLICENCE)springer-10.1007/s00508-015-0789-4 Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia [Elektronische Daten] [Arno Amann, Normann Steiner, Eberhard Gunsilius] Summary: Background: Recurrent epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients significantly decreases their quality of life. Treatment in therapy refractory patients is limited although various options have been tested so far. Case report: Herein, one patient is described that was treated for HHT for over 20 years with only intermediate benefits. As epistaxis duration and frequency increased continuously, bevacizumab 5mg/kg was administered every 2 weeks. During the time of treatment (six doses) and up to 3 month afterwards clinical symptoms, blood pressure, cardiac output, pulmonary arterial hypertension (PAH), bleeding duration and frequency were assessed as criteria for treatment benefit. Results: Duration and frequency of epistaxis decreased immediately after the first application resulting in reduced need of blood transfusions. After completion of six cycles, a further decrease in frequency and duration of bleeding was noted. Cardiac output and PAH decreased or remained stable, respectively, during time and after treatment. No increase in blood pressure could be found but a significant increase in heart rate was experienced after completion of all six applications. Unfortunately, the patient died due to a cerebral abscess. Conclusion: Bevacizumab led to an improvement of HHT related epistaxis, refractory to other treatments. Springer-Verlag Wien, 2015 3D cell culture nationallicence Tumour stroma nationallicence Microenvironment nationallicence Prediciting drug sensitivity nationallicence Personalized cancer therapy nationallicence Amann Arno Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria aut Steiner Normann Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria aut Gunsilius Eberhard Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria aut Wiener klinische Wochenschrift Springer Vienna 127/15-16(2015-08-01), 631-634 0043-5325 127:15-16<631 2015 127 508 https://doi.org/10.1007/s00508-015-0789-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 brief-communication jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-015-0789-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Amann Arno Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria aut NATIONALLICENCE 700 1- Steiner Normann Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria aut NATIONALLICENCE 700 1- Gunsilius Eberhard Department of Internal Medicine V (Haematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/15-16(2015-08-01), 631-634 0043-5325 127:15-16<631 2015 127 508